Long-term retention rate of pramipexole in the treatment of Parkinson's disease.
Tapani
T
Keränen
Mervi
M
Tuhkasaari
Hanna
H
Kuusisto
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D052160:Benzothiazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D003221:Confusion / Q000139:chemically induced; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects*; D005387:Finland; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D055118:Medication Adherence; D009325:Nausea / Q000139:chemically induced; D009426:Netherlands; D010300:Parkinson Disease / Q000188:drug therapy*; D000077487:Pramipexole; D012189:Retrospective Studies; D012307:Risk Factors
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D018491:Dopamine Agonists; D000077487:Pramipexole